In vitro activity of cefiderocol against carbapenem-resistant Acinetobacter baumannii clinical isolates: a single center experience.
Main Article Content
Keywords
Cefiderocol, CRAB, Antimicrobial resistance, Guidelines
Abstract
Introduction: Cefiderocol (CFDC) is a novel siderophore cephalosporin with broad-spectrum activity against carbapenem-resistant Gram-negative bacteria. Gram-negative bacterial isolates' resistance to cefiderocol (CFDC) is emerging in clinical practice.
Downloads
Abstract 377
PDF Downloads 480
HTML Downloads 147
References
2. Reale, M., Strazzulla, A., Quirino, A., Rizzo, C., Marano, V., Postorino, M. C., Mazzitelli, M., Greco, G., Pisani, V., Costa, C., et al. Patterns of multi-drug resistant bacteria at first culture from patients admitted to a third level University hospital in Calabria from 2011 to 2014: implications for empirical therapy and infection control. Infez Med. 2017, 25, 98,107.
3. Scaglione, V., Reale, M., Davoli, C., Mazzitelli, M., Serapide, F., Lionello, R., La Gamba, V., Fusco, P., Bruni, A., Procopio, D., et al. Prevalence of Antibiotic Resistance Over Time in a Third-Level University Hospital. Microb Drug Resist. 2022, 28, 425,435.
4. Serapide, F., Quirino, A., Scaglione, V., Morrone, H. L., Longhini, F., Bruni, A., Garofalo, E., Matera, G., Marascio, N., Scarlata, G. G. M. et al. Is the Pendulum of Antimicrobial Drug Resistance Swinging Back after COVID-19?. Microorganisms. 2022, 10, 957.
5. Hsueh SC, Lee YJ, Huang YT, Liao CH, Tsuji M, Hsueh PR. In vitro activities of cefiderocol, ceftolozane/tazobactam, ceftazidime/avibactam and other comparative drugs against imipenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii, and Stenotrophomonas maltophilia, all associated with bloodstream infections in Taiwan. J Antimicrob Chemother. 2019,74,380, 386.
6. Trecarichi, E. M., Quirino, A., Scaglione, V., Longhini, F., Garofalo, E., Bruni, A., Biamonte, E., Lionello, R., Serapide, F., Mazzitelli, M., et al., Successful treatment with cefiderocol for compassionate use in a critically ill patient with XDR Acinetobacter baumannii and KPC-producing Klebsiella pneumoniae: a case report. The Journal of antimicrobial chemotherapy, 2019, 74, 3399,3401.
7. Wang C, Yang D, Wang Y, Ni W. Cefiderocol for the Treatment of Multidrug-Resistant Gram-Negative Bacteria: A Systematic Review of Currently Available Evidence. Frontiers in pharmacology, 2022, 13, 896971.
8. The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 13.0, 2023. http://www.eucast.org.
9. EUCAST warnings concerning antimicrobial susceptibility testing products or procedures(August 2022) https://www.eucast.org/ast-of-bacteria/warnings
10. The European Committee on Antimicrobial Susceptibility Testing. Breakpoints for cefiderocol from EUCAST https://www.eucast.org/eucast_news/news_singleview/?tx_ttnews%5Btt_news%5D=493&cHash=22779384b74c8cf2c55aa3f7fd69d173
11. CLSI m100-ed32:2022 performance standards for antimicrobial susceptibility testing, 32nd edition
12. Abdul-Mutakabbir, J. C., Nguyen, L., Maassen, P. T., Stamper, K. C., Kebriaei, R., Kaye, K. S., Castanheira, M., & Rybak, M. J. In Vitro Antibacterial Activity of Cefiderocol against Multidrug-Resistant Acinetobacter baumannii. Antimicrobial agents and chemotherapy, 2021, 65, e0264620
13. Candel, F. J., Santerre Henriksen, A., Longshaw, C., Yamano, Y., & Oliver, A. In vitro activity of the novel siderophore cephalosporin, cefiderocol, in Gram-negative pathogens in Europe by site of infection. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, (2022). 28(3), 447,e1, 447,e6.
14. Carcione, D., Siracusa, C., Sulejmani, A., Migliavacca, R., Mercato, A., Piazza, A., Principe, L., Clementi, N., Mancini, N., Leoni, V., et al., In Vitro Antimicrobial Activity of the Siderophore Cephalosporin Cefiderocol against Acinetobacter baumannii Strains Recovered from Clinical Samples. Antibiotics (Basel, Switzerland), 2021 10(11), 1309.
15. Cercenado, E., Cardenoso, L., Penin, R., Longshaw, C., Henriksen, A. S., & Pascual, A. In vitro activity of cefiderocol and comparators against isolates of Gram-negative bacterial pathogens from a range of infection sources: SIDERO WT 2014-2018 studies in Spain. Journal of global antimicrobial resistance, 2021 26, 292, 300.
16. Ghebremedhin, B., & Ahmad-Nejad, P. In-Vitro Efficacy of Cefiderocol in Carbapenem-Non-Susceptible Gram-Negative Bacilli of Different Genotypes in Sub-Region of North Rhine Westphalia, Germany. Pathogens (Basel, Switzerland), 10 2021 (10), 1258.
17. Morris, C. P., Bergman, Y., Tekle, T., Fissel, J. A., Tamma, P. D., & Simner, P. J. Cefiderocol Antimicrobial Susceptibility Testing against Multidrug-Resistant Gram-Negative Bacilli: a Comparison of Disk Diffusion to Broth Microdilution. Journal of clinical microbiology, 2020, 59(1), e01649,20
18. Naas T, Lina G, Santerre Henriksen A, Longshaw C, Jehl F. In vitro activity of cefiderocol and comparators against isolates of Gram-negative pathogens from a range of infection sources: SIDERO-WT-2014-2018 studies in France [published correction appears in JAC Antimicrob Resist. JAC Antimicrob Resist. 2021;3(2),dlab081
19. Wang, Y., Li, Y., Zhao, J., Guan, J., Ni, W., & Gao, Z. Susceptibility of cefiderocol and other antibiotics against carbapenem-resistant, Gram-negative bacteria. Annals of translational medicine, (2022). 10(5), 261.
20. Bleibtreu, A., Dortet, L., Bonnin, R. A., Wyplosz, B., Sacleux, S. C., Mihaila, L., Dupont, H., Junot, H., Bunel, V., Grall, N et al., Susceptibility Testing Is Key for the Success of Cefiderocol Treatment: A Retrospective Cohort Study. Microorganisms,2021 9(2), 282.
Article Sidebar
Article Details
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers. Authors will grant copyright of their articles to the Institute of Hematology, Catholic University, Rome . No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.